{"id":"active-comparator-drv-cb","safety":{"commonSideEffects":[{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Rash"},{"rate":null,"effect":"Elevated liver enzymes"}]},"_chembl":{"chemblId":"CHEMBL1165603","moleculeType":"Small molecule","molecularWeight":"725.68"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Darunavir inhibits HIV protease, an enzyme essential for processing viral polyproteins and producing mature, infectious viral particles. Cobicistat is a cytochrome P450 inhibitor that boosts darunavir plasma concentrations, allowing for lower doses and improved tolerability. Together, they reduce viral load and slow disease progression in HIV-infected patients.","oneSentence":"DRV/c (darunavir boosted with cobicistat) is a protease inhibitor combined with a pharmacokinetic booster that blocks HIV protease to prevent viral replication.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:26:35.511Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HIV-1 infection in treatment-experienced and treatment-naïve adults"},{"name":"HIV-1 infection in combination antiretroviral therapy"}]},"trialDetails":[{"nctId":"NCT03842488","phase":"PHASE4","title":"Raltegravir One Thousand Two Hundred vs Darunavir-cb in Immnunosupressed Patients: ROTDIP Study","status":"UNKNOWN","sponsor":"Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud","startDate":"2019-04","conditions":"HIV Infections","enrollment":75}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["DARUNAVIR/COBICISTAT 800 Mg-150 Mg Oral Tablet"],"phase":"marketed","status":"active","brandName":"Active comparator: DRV/cb","genericName":"Active comparator: DRV/cb","companyName":"Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud","companyId":"fundaci-n-p-blica-andaluza-para-la-investigaci-n-de-m-laga-en-biomedicina-y-salu","modality":"Small molecule","firstApprovalDate":"","aiSummary":"DRV/c (darunavir boosted with cobicistat) is a protease inhibitor combined with a pharmacokinetic booster that blocks HIV protease to prevent viral replication. Used for HIV-1 infection in treatment-experienced and treatment-naïve adults, HIV-1 infection in combination antiretroviral therapy.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}